¿Cómo se compara el ratio PE de CSL con empresas similares?

CSL es un buen valor basado en su ratio Price-To-Earnings (32.2x) comparado con la media de empresas similares (56.9x).

¿Cómo se compara el ratio PE de CSL con el de otras empresas de la industria Global Biotechs ?

CSL es cara en función de su ratio Price-To-Earnings (32.2x) en comparación con la media de la industria Global Biotechs (26.3x).

¿Cuál es el ratio PE de CSL comparado con su ratio PE justo? Este es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

CSL es cara según su ratio Price-To-Earnings (32.2x) comparado con el ratio justo estimado Price-To-Earnings (31.9x).

¿Cuál es el precio justo de CSL si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

CSL (A$272.45) cotiza por debajo de nuestra estimación de [[valor justo]] (A$408.13)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

El precio objetivo es más de un 20% superior al precio actual de la acción, y los analistas están dentro de un rango de acuerdo estadísticamente seguro.

CSL (ASX:CSL) - Cotización, noticias y análisis

Resumen de acción CSL

Análisis fundamental de CSL
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	3/6
Rendimiento pasado	5/6
Salud financiera	4/6
Dividendos	4/6

Recompensas

Cotiza un 33.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 13%

Los beneficios aumentaron un 20.4% el pasado año

Los analistas coinciden en que el precio de las acciones subirá un 20.3%

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Competidores de CSL Limited

Telix Pharmaceuticals

ASX:TLX

AU$7.6b

Clinuvel Pharmaceuticals

ASX:CUV

AU$677.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.4b

Amgen

NasdaqGS:AMGN

US$152.4b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de CSL
Precios históricos de las acciones
Precio actual de la acción	AU$272.45
Máximo en las últimas 52 semanas	AU$313.55
Mínimo de 52 semanas	AU$255.17
Beta	0.30
1Cambio en 1 mes	-9.36%
Variación en 3 meses	-11.61%
Cambio de 1 año	5.76%
3Variación en 3 años	-13.80%
Variación en 5 años	-0.35%
Variación desde la OPV	33,956.59%

Noticias y actualizaciones recientes

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Rentabilidad de los accionistas

	CSL	AU Biotechs	Mercado AU
7D	-5.2%	-2.6%	-0.07%
1Y	5.8%	11.2%	16.9%

Rentabilidad vs. Industria: Los resultados de CSL fueron inferiores a los de la industria Australian Biotechs, que obtuvo un rendimiento del 11.2% el año pasado.

Rentabilidad vs. Mercado: CSL obtuvo unos resultados inferiores a los del mercado Australian, que fueron del 16.9% el año pasado.

Volatilidad de los precios

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.0%
Biotechs Industry Average Movement	10.1%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: CSL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CSL (2%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited investiga, desarrolla, fabrica, comercializa y distribuye productos biofarmacéuticos y vacunas en Australia, Estados Unidos, Alemania, Reino Unido, Suiza, China, Hong Kong y a escala internacional. La empresa opera a través de los segmentos CSL Behring, CSL Seqirus y CSL Vifor. El segmento CSL Behring ofrece productos plasmáticos, terapias génicas y recombinantes.

Resumen de fundamentos de CSL Limited

¿Cómo se comparan los beneficios e ingresos de CSL con su capitalización de mercado?
Estadísticas fundamentales de CSL
Capitalización bursátil	AU$131.92b
Beneficios(TTM)	AU$4.09b
Ingresos (TTM)	AU$22.92b

32.2x

Ratio precio-beneficio (PE)

5.8x

Ratio precio-ventas (PS)

¿Está CSL sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CSL
Ingresos	US$14.80b
Coste de los ingresos	US$7.10b
Beneficio bruto	US$7.71b
Otros gastos	US$5.06b
Beneficios	US$2.64b

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

Feb 10, 2025

Beneficios por acción (BPA)	5.46
Margen bruto	52.06%
Margen de beneficio neto	17.85%
Ratio deuda/patrimonio	54.2%

¿Cómo se ha desempeñado CSL a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.5%

Rentabilidad actual por dividendo

48%

Ratio de pagos

Resumen de acción CSL

Recompensas

Análisis de riesgos

Competidores de CSL Limited

ASX:TLX

AU$7.6b

ASX:CUV

AU$677.8m

NasdaqGS:REGN

US$81.4b

NasdaqGS:AMGN

US$152.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases